Dienogest

證據等級: L5

預測適應症: 10 個

DIENOGEST: Repurposing Candidate — Insufficient Data for Full Evaluation

One-Sentence Summary

Dienogest (DrugBank DB09123) is a synthetic progestogen; however, the current Evidence Pack contains no original indication records from the regulatory database and no TxGNN-predicted new indications, making a standard repurposing evaluation impossible at this stage. Critical data gaps in mechanism of action, safety warnings, and regulatory history must be resolved before any evidence-based conclusion can be drawn.

Quick Overview

Item	Content
Original Indication	Not available (no Taiwan regulatory records found)
Predicted New Indication	Not available (TxGNN predictions not yet generated)
TxGNN Prediction Score	—
Evidence Level	L5 — Model prediction not yet run; no supporting studies retrievable
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN-predicted indication is available in this Evidence Pack (predicted_indications: []). Without a target disease, a mechanistic rationale cannot be constructed.

Currently, detailed mechanism of action data is also not available. Based on DrugBank record DB09123, Dienogest is classified as a progestogen (fourth-generation synthetic progestin). Its pharmacological activity is mediated through progesterone receptor agonism, and it is widely used in European and Asian markets for endometriosis and hormonal contraception — though none of these indications appear in the Taiwan regulatory database queried.

To proceed with this section, the TxGNN prediction pipeline must first be run and a target disease must be confirmed before any mechanistic bridge can be evaluated.

Clinical Trial Evidence

Currently no related clinical trials registered under this Evidence Pack. This is because no predicted indication has been identified; once a target disease is confirmed, a ClinicalTrials.gov query can be executed.

Literature Evidence

Currently no related literature available. Target indication must be specified before a PubMed query can yield meaningful results.

Taiwan Market Information

No authorizations found. The TFDA query (2026-03-29) returned 0 records for DIENOGEST.

Safety Considerations

Please refer to the package insert for safety information.

No drug interaction data was found in the DDI database query (2026-03-29). TFDA package insert parsing was recorded as successful (query ID 4), but extracted warning and contraindication fields are unavailable in this Evidence Pack version.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Dienogest is missing all three elements required for a repurposing evaluation: a TxGNN-predicted target indication, mechanism of action data, and safety/regulatory content. There is no basis on which to assess efficacy plausibility, evidence strength, or risk profile at this time.

To proceed, the following is needed:

Run TxGNN prediction pipeline — Generate ranked candidate indications for DB09123 so a target disease can be selected
Retrieve MOA from DrugBank API — Populate original_moa to enable mechanistic rationale (Data Gap DG002, severity: High)
Download and parse TFDA package insert PDF — Extract warnings and contraindications to unblock the safety evaluation (Data Gap DG001, severity: Blocking)
Confirm original indication — Query DrugBank or WHO INN records to populate original_indications (currently empty)
Re-run Evidence Pack generation (target version: v5) — Once gaps above are resolved, resubmit for a complete L1–L5 evidence grading and Go/Hold/Proceed recommendation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.